Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is...
NYSE: NVO
Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China
The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...
Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer
Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion
Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...
Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes
The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...
CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars
The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...
FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind
The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...
Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024
Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...
Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study
Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...